Abstract
The efficacy and safety of betamethasone dipropionate, 0.05% in a propylene glycol base (Diprolene), was investigated in an open, fixed-dose study of thirty-one patients with resistant psoriasis. Clearing of lesions or marked improvement occurred in 97% (thirty out of thirty-one) of patients. Increased penetration of corticosteroid did not cause adrenal suppression or other adverse reactions.